BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33030975)

  • 1. HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma.
    Salminen L; Gidwani K; Grènman S; Carpén O; Hietanen S; Pettersson K; Huhtinen K; Hynninen J
    Acta Oncol; 2020 Dec; 59(12):1461-1468. PubMed ID: 33030975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
    Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].
    Zheng H; Gao YN; Gao WJ; Gao M; Yan X
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):445-9. PubMed ID: 24119905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of HE4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer.
    Kotowicz BU; Fuksiewicz M; Bidzinski M; Berezowska A; Sobiczewski P; Kowalska MM
    Ginekol Pol; 2022; 93(11):910-915. PubMed ID: 36621970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Alegría-Baños JA; Jiménez-López JC; Vergara-Castañeda A; de León DFC; Mohar-Betancourt A; Pérez-Montiel D; Sánchez-Domínguez G; García-Villarejo M; Olivares-Pérez C; Hernández-Constantino Á; González-Santiago A; Clara-Altamirano M; Arela-Quispe L; Prada-Ortega D
    J Ovarian Res; 2021 Jul; 14(1):96. PubMed ID: 34275472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HE4 is associated with clinical prognostic factors and survival outcome in female patients with primary peritoneal carcinoma.
    Mi D; Zhang Y; Chen S
    Int J Gynaecol Obstet; 2022 Aug; 158(2):352-358. PubMed ID: 34735726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer.
    Potenza E; Parpinel G; Laudani ME; Macchi C; Fuso L; Zola P
    Int J Biol Markers; 2020 Dec; 35(4):20-27. PubMed ID: 33126819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
    Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
    J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma.
    Orsaria M; Londero AP; Marzinotto S; Di Loreto C; Marchesoni D; Mariuzzi L
    Cancer Biomark; 2016; 17(4):479-486. PubMed ID: 27802199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.